These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9951803)
1. Effects and mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation. Xiaoli M; Wenying H; Mingpeng S Int J Cardiol; 1998 Oct; 66 Suppl 1():S57-64; discussion S65. PubMed ID: 9951803 [TBL] [Abstract][Full Text] [Related]
2. Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. Herbert JM; Lamarche I; Prabonnaud V; Dol F; Gauthier T J Biol Chem; 1994 Jan; 269(4):3076-80. PubMed ID: 8300642 [TBL] [Abstract][Full Text] [Related]
3. Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells. Ekhterae D; Stanley JC J Vasc Surg; 1995 Jun; 21(6):953-62. PubMed ID: 7776475 [TBL] [Abstract][Full Text] [Related]
4. The effect of endothelial cell overexpression of plasminogen activator inhibitor-1 on smooth muscle cell migration. Proia RR; Nelson PR; Mulligan-Kehoe MJ; Wagner RJ; Kehas AJ; Powell RJ J Vasc Surg; 2002 Jul; 36(1):164-71. PubMed ID: 12096275 [TBL] [Abstract][Full Text] [Related]
5. T-cell lymphokines, interleukin-4 and gamma interferon, modulate the induction of vascular smooth muscle cell tissue plasminogen activator and migration by serum and platelet-derived growth factor. Wang W; Chen HJ; Giedd KN; Schwartz A; Cannon PJ; Rabbani LE Circ Res; 1995 Dec; 77(6):1095-106. PubMed ID: 7586221 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation. Ji Y; Weng Z; Fish P; Goyal N; Luo M; Myears SP; Strawn TL; Chandrasekar B; Wu J; Fay WP Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2167-2175. PubMed ID: 27659097 [TBL] [Abstract][Full Text] [Related]
7. Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo. Christ G; Hufnagl P; Kaun C; Mundigler G; Laufer G; Huber K; Wojta J; Binder BR Arterioscler Thromb Vasc Biol; 1997 Apr; 17(4):723-30. PubMed ID: 9108786 [TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. Kauhanen P; Sirén V; Carpén O; Vaheri A; Lepäntalo M; Lassila R Circulation; 1997 Sep; 96(6):1783-9. PubMed ID: 9323062 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. van Leeuwen RT; Kol A; Andreotti F; Kluft C; Maseri A; Sperti G Circulation; 1994 Jul; 90(1):362-8. PubMed ID: 8026020 [TBL] [Abstract][Full Text] [Related]
10. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Wojta J; Gallicchio M; Zoellner H; Hufnagl P; Last K; Filonzi EL; Binder BR; Hamilton JA; McGrath K Thromb Haemost; 1993 Sep; 70(3):469-74. PubMed ID: 8259551 [TBL] [Abstract][Full Text] [Related]
11. Combined effect of retinoic acid and basic FGF on PAI-1 gene expression in vascular smooth muscle cells. Watanabe A; Kurabayashi M; Arai M; Sekiguchi K; Nagai R Cardiovasc Res; 2001 Jul; 51(1):151-9. PubMed ID: 11399257 [TBL] [Abstract][Full Text] [Related]
12. Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Redmond EM; Cullen JP; Cahill PA; Sitzmann JV; Stefansson S; Lawrence DA; Okada SS Circulation; 2001 Jan; 103(4):597-603. PubMed ID: 11157728 [TBL] [Abstract][Full Text] [Related]
13. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis. Au YP; Kenagy RD; Clowes AW J Biol Chem; 1992 Feb; 267(5):3438-44. PubMed ID: 1310687 [TBL] [Abstract][Full Text] [Related]
14. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways. Demyanets S; Kaun C; Rychli K; Rega G; Pfaffenberger S; Afonyushkin T; Bochkov VN; Maurer G; Huber K; Wojta J Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1962-8. PubMed ID: 17604327 [TBL] [Abstract][Full Text] [Related]
15. Effect of tissue plasminogen activator on vascular smooth muscle cells. Yang Z; Eton D; Zheng F; Livingstone AS; Yu H J Vasc Surg; 2005 Sep; 42(3):532-8. PubMed ID: 16171602 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Biro S; Fu YM; Yu ZX; Epstein SE Proc Natl Acad Sci U S A; 1993 Jan; 90(2):654-8. PubMed ID: 8421701 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of neointima formation with tissue-type plasminogen activator. Hilfiker PR; Waugh JM; Li-Hawkins JJ; Kuo MD; Yuksel E; Geske RS; Cifra PN; Chawla M; Weinfeld AB; Thomas JW; Shenaq SM; Dake MD J Vasc Surg; 2001 Apr; 33(4):821-8. PubMed ID: 11296338 [TBL] [Abstract][Full Text] [Related]
18. Pathogenetic implications of hyaluronan-induced modification of vascular smooth muscle cell fibrinolysis in diabetes. Marutsuka K; Woodcock-Mitchell J; Sakamoto T; Sobel BE; Fujii S Coron Artery Dis; 1998; 9(4):177-84. PubMed ID: 9649923 [TBL] [Abstract][Full Text] [Related]
19. Expression of the plasminogen activator system in the human vascular wall. Salame MY; Samani NJ; Masood I; deBono DP Atherosclerosis; 2000 Sep; 152(1):19-28. PubMed ID: 10996335 [TBL] [Abstract][Full Text] [Related]
20. T cell lymphokines modulate bFGF-induced smooth muscle cell fibrinolysis and migration. Wang W; Chen HJ; Schwartz A; Cannon PJ; Rabbani LE Am J Physiol; 1997 Feb; 272(2 Pt 1):C392-8. PubMed ID: 9124280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]